Study of Cetuximab in Squamous Cell Carcinoma of the Skin Expressing EGFR

Inclusion Criteria: * Histological SCC of the skin expressing (IHC) moderately or highly the EGFR (++ and +++, on a semi-quantitative scale). * Locally advanced or metastatic SCC of the skin not suitable for local surgery with documented progression. * Presence of at least one measurable target lesion by RECIST criteria. * At least one lesion accessible to biopsies. * ECOG Performance status \< 2. * Life expectancy \> 3 months. * Age \> 18 years. * Normal hematological (Neutrophils \> 1.5x109 cells/l, platelets \> 100x109 cells/l), hepatic (bilirubin \< 1.5 times the upper limit of the normal range (ULN); alkaline phosphatase and transaminases \< 5 x UNL in case of hepatic metastases or \< 2.5 x UNL in absence of hepatic metastases) and renal (serum creatinine \< 150 micromol/L) functions. * Written informed consent. * In case of second tumor,excepted carcinoma of the cervix and adequately treated basal or squamous cell skin carcinoma, the possibility for including a patient may be discussed with the principal investigator. Exclusion Criteria: * Prior chemotherapy * Prior radiotherapy \< 1 month. * Prior therapy with agent targeting EGFR * Unstable systemic diseases or active uncontrolled infections. * Patients (male and female) not using effective contraception if of reproductive potential. * Females pregnant or lactating. Women of child bearing potential must have a negative serum or urine pregnancy test prior to start each cycle of treatment.